Skip to main content

Table 1 Patient and tumor characteristics

From: Identification by array comparative genomic hybridization of a new amplicon on chromosome 17q highly recurrent in BRCA1 mutated triple negative breast cancer

 

BRCA1

BRCA1

BRCA1

Mutated

Non mutated

Unscreened

Clinical characteristics

TN

Lum A

HER2+

TN

TN

Lum A

Lum B

HER2+

Tumors analyzed, n

23

7

2

21

15

20

22

21

Age, years, mean

44

44

48

50

59

63

59

59

(range)

(28 to 60)

(29 to 71)

(42 to 54)

(28 to 72)

(31 to 83)

(43 to 86)

(37 to 85)

(34 to 84)

Histology, n (%)

Ductal

20

7

2

19

14

18

21

19

(87%)

(100%)

(100%)

(90%)

(93%)

(90%)

(69%)

(90%)

Lobular

1

2

0

1

0

2

1

2

(4%)

(29%)

(0%)

(5%)

(0%)

(10%)

(5%)

(10%)

Metaplastic

0

0

0

1

0

0

0

0

(0%)

(0%)

(0%)

(5%)

(0%)

(0%)

(0%)

(0%)

Medullary

2

0

0

0

0

0

0

0

(8.7%)

(0%)

(0%)

(0%)

(0%)

(0%)

(0%)

(0%)

Grade I

0

0

0

1

0

12

1

3

(0%)

(0%)

(0%)

(5%)

(0%)

(60%)

(5%)

(14%)

Grade II

0

3

0

3

3

7

9

9

(0%)

(43%)

(0%)

(14%)

(20%)

(35%)

(41%)

(43%)

Grade III

23

4

2

17

12

1

12

9

(100%)

(57%)

(100%)

(81%)

(80%)

(5%)

(55%)

(43%)

Immunohistochemistry, n (%)

ER-positive, n (%)

0

7

0

0

0

20

22

12

(0%)

(100%)

(0%)

(0%)

(0%)

(100%)

(100%)

(57%)

PR-positive, n (%

0

5

0

0

0

20

22

12

(0%)

(71%)

(0%)

(0%)

(0%)

(100%)

(100%)

(57%)

HER2-positive, n (%)

0

0

2

0

0

0

0

21

(0%)

(0%)

(100%)

(0%)

(0%)

(0%)

(0%)

(100%)

KI67, mean, %

42

7

47

35

48

7

44

34

P63- or EGFR- or CK14- or CK5/6-positive, n (%)

11

1

1

7

9

0

1

3

(48%)

(14%)

(50%)

(33%)

(60%)

(0%)

(5%)

(14%)

Array CGH

Gain in 17q25.3, n (%)

20

7

2

6

4

0

3

4

(87%)

(100%)

(100%)

(29%)

(27%)

(0%)

(14%)

(19%)

  1. TN, triple-negative; Lum, luminal; HER2+, human epidermal growth factor 2-positive; ER, estrogen receptor; PR, progesterone receptor; EGFR, epidermal growth factor receptor; CK, cytokeratin; ACGH, array comparative genomic hybridization.